Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy. (PubMed, Cells) - Jan 24, 2025 - "However, whether blocking the intrinsic ferroptosis pathways of MDSCs can relieve imidazole ketone erastin (IKE)-initiated ferroptosis-induced immune suppression and ultimately trigger the optimal therapeutic effect of the combined ferroptosis and ICB therapy is still unknown...More importantly, TIPE2-deficient MDSCs achieved the full anti-tumor therapeutic potential of IKE-induced ferroptosis therapy and a PD-L1 blockade. These findings indicate that TIPE2 confers the ferroptosis sensitivity of MDSCs, and combining the targeting of the TIPE2 of MDSCs, ferroptosis therapy, and ICB is a novel therapeutic option for cancer treatment."
Journal • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPX4 • PLTP • SLC7A11
|
|
Abdulrahman Ibrahim; Dehong Yan; Hafiza Kashaf Tariq; Lawan Rabiu; Nada Mohamady Farouk Abdalsalam; Qiong Yang; Rong Li; Xiaochun Wan; Zihao Liang
|